0000919574-25-000110.txt : 20250106 0000919574-25-000110.hdr.sgml : 20250106 20250106165011 ACCESSION NUMBER: 0000919574-25-000110 CONFORMED SUBMISSION TYPE: SCHEDULE 13G PUBLIC DOCUMENT COUNT: 3 FILED AS OF DATE: 20250106 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Fulcrum Therapeutics, Inc. CENTRAL INDEX KEY: 0001680581 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 474839948 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SCHEDULE 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-91080 FILM NUMBER: 25511961 BUSINESS ADDRESS: STREET 1: 26 LANDSDOWNE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-651-8851 MAIL ADDRESS: STREET 1: 26 LANDSDOWNE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: SUVRETTA CAPITAL MANAGEMENT, LLC CENTRAL INDEX KEY: 0001569064 ORGANIZATION NAME: IRS NUMBER: 453704500 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SCHEDULE 13G BUSINESS ADDRESS: STREET 1: 540 MADISON AVENUE STREET 2: 7TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: 2127025204 MAIL ADDRESS: STREET 1: 540 MADISON AVENUE STREET 2: 7TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 SCHEDULE 13G 1 primary_doc.xml SCHEDULE 13G 0001569064 XXXXXXXX LIVE Common Stock, par value $0.001 per share 12/27/2024 0001680581 Fulcrum Therapeutics, Inc. 359616109 26 Landsdowne Street Cambridge MA 02139 Rule 13d-1(c) SUVRETTA CAPITAL MANAGEMENT, LLC b DE 0.00 3404612.00 0.00 3404612.00 3404612.00 N 6.3 IA OO Averill Master Fund, Ltd. b E9 0.00 3151741.00 0.00 3151741.00 3151741.00 N 5.8 CO Aaron Cowen b X1 0.00 3404612.00 0.00 3404612.00 3404612.00 N 6.3 HC IN Fulcrum Therapeutics, Inc. 26 Landsdowne Street, Cambridge, MA 02139 Suvretta Capital Management, LLC Averill Master Fund, Ltd. Aaron Cowen Suvretta Capital Management, LLC 540 Madison Avenue, 7th Floor New York, New York 10022 United States of America Averill Master Fund, Ltd. c/o Maples Corporate Services Limited P.O. Box 309 Ugland House Grand Cayman KY1-1104 Cayman Islands Aaron Cowen c/o Suvretta Capital Management, LLC 540 Madison Avenue, 7th Floor New York, New York 10022 Suvretta Capital Management, LLC - Delaware Averill Master Fund, Ltd. - Cayman Islands Aaron Cowen - United States Y Suvretta Capital Management, LLC - 3,404,612 Averill Master Fund, Ltd. - 3,151,741 Aaron Cowen - 3,404,612 Suvretta Capital Management, LLC - 6.3% Averill Master Fund, Ltd. - 5.8% Aaron Cowen - 6.3% Suvretta Capital Management, LLC - 0 Averill Master Fund, Ltd. - 0 Aaron Cowen - 0 Suvretta Capital Management, LLC - 3,404,612 Averill Master Fund, Ltd. - 3,151,741 Aaron Cowen - 3,404,612 Suvretta Capital Management, LLC - 0 Averill Master Fund, Ltd. - 0 Aaron Cowen - 0 Suvretta Capital Management, LLC - 3,404,612 Averill Master Fund, Ltd. - 3,151,741 Aaron Cowen - 3,404,612 Y N All of the securities reported in this Schedule 13G are directly owned by advisory clients of Suvretta Capital Management, LLC. None of those advisory clients, other than Averill Master Fund, Ltd., may be deemed to beneficially own more than 5% of the Common Stock, $0.001 par value per share. N Please see Exhibit B attached hereto. Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. [Exhibit A - Joint Filing Agreement] [Exhibit B - Control Person Identification] SUVRETTA CAPITAL MANAGEMENT, LLC /s/ Aaron Cowen Aaron Cowen/Authorized Signatory 01/06/2025 Averill Master Fund, Ltd. /s/ Aaron Cowen Aaron Cowen/Director 01/06/2025 Aaron Cowen /s/ Aaron Cowen Aaron Cowen 01/06/2025 * Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his, her or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. To the extent that "ownership of 5 percent or less of a class" was indicated in Item 5, such response only applies to the Reporting Person(s) that indicated elsewhere herein that it beneficially owns five percent (5%) or less of the class. EX-99 2 d11556937_ex99-a.htm

Exhibit A

JOINT FILING AGREEMENT

The undersigned agree that this Schedule 13G dated January 6, 2025 relating to the Common Stock, par value $0.001 per share, of Fulcrum Therapeutics, Inc. shall be filed on behalf of the undersigned.

 

SUVRETTA CAPITAL MANAGEMENT, LLC

 

By: /s/ Aaron Cowen

  Name: Aaron Cowen
  Title:   Authorized Signatory

 

 

 

AVERILL MASTER FUND, LTD.

 

By: /s/ Aaron Cowen

  Name: Aaron Cowen
  Title:   Director

 

 

 

AARON COWEN

 

By: /s/ Aaron Cowen

 

 

 EX-99 3 d11556937_ex99-b.htm

Exhibit B

CONTROL PERSON IDENTIFICATION

Suvretta Capital Management, LLC is the relevant entity for which Aaron Cowen is the control person.